Published in Clin Exp Dermatol on March 23, 2009
Ebastine in chronic spontaneous urticaria in higher doses. Indian J Dermatol (2011) 0.93
Comparative Efficacy and Safety of Ebastine 20 mg, Ebastine 10 mg and Levocetirizine 5 mg in Acute Urticaria. J Clin Diagn Res (2017) 0.75
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy (2008) 12.35
Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature (2000) 5.86
Different requirements for EDS1 and NDR1 by disease resistance genes define at least two R gene-mediated signaling pathways in Arabidopsis. Proc Natl Acad Sci U S A (1998) 4.70
EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy (2009) 4.10
EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy (2009) 3.86
Rapid identification of methicillin-resistant Staphylococcus aureus and simultaneous species confirmation using real-time fluorescence PCR. J Clin Microbiol (2000) 3.82
CENP-C, an autoantigen in scleroderma, is a component of the human inner kinetochore plate. Cell (1992) 3.70
Role of nonallergic hypersensitivity reactions in children with chronic urticaria. Allergy (1998) 3.20
The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy (2014) 3.10
A comprehensive guide for the recognition and classification of distinct stages of hair follicle morphogenesis. J Invest Dermatol (1999) 2.92
Practical guide to skin prick tests in allergy to aeroallergens. Allergy (2011) 2.51
Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy (2010) 2.34
Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol (2012) 2.17
Assessment of histamine-releasing activity of sera from patients with chronic urticaria showing positive autologous skin test on human basophils and mast cells. Clin Exp Allergy (2004) 2.13
Chronic rhinosinusitis in Europe--an underestimated disease. A GA²LEN study. Allergy (2011) 2.13
Home versus hospital deliveries: follow up study of matched pairs for procedures and outcome. Zurich Study Team. BMJ (1996) 2.10
Mast cells as sentinels of innate immunity. Curr Opin Immunol (1999) 1.85
Factors responsible for differences between asymptomatic subjects and patients presenting an IgE sensitization to allergens. A GA2LEN project. Allergy (2006) 1.84
Impaired mast cell-dependent natural immunity in complement C3-deficient mice. Nature (1997) 1.78
GA(2)LEN skin test study I: GA(2)LEN harmonization of skin prick testing: novel sensitization patterns for inhalant allergens in Europe. Allergy (2009) 1.72
A case-control study of the relation between plasma selenium and asthma in European populations: a GAL2EN project. Allergy (2008) 1.66
EAACI/GA(2)LEN task force consensus report: the autologous serum skin test in urticaria. Allergy (2009) 1.65
Autologous whole blood injections to patients with chronic urticaria and a positive autologous serum skin test: a placebo-controlled trial. Dermatology (2006) 1.65
Night-time sedating H1 -antihistamine increases daytime somnolence but not treatment efficacy in chronic spontaneous urticaria: a randomized controlled trial. Br J Dermatol (2014) 1.60
Molecular cloning, chromosome mapping and characterization of UBQLN3 a testis-specific gene that contains an ubiquitin-like domain. Gene (2000) 1.57
Insulin allergy: clinical manifestations and management strategies. Allergy (2008) 1.56
A quantitative description of the ground-state wave function of Cu(A) by X-ray absorption spectroscopy: comparison to plastocyanin and relevance to electron transfer. J Am Chem Soc (2001) 1.55
How to assess disease activity in patients with chronic urticaria? Allergy (2008) 1.55
C3a and C5a stimulate chemotaxis of human mast cells. Blood (1997) 1.55
EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy (2006) 1.55
Embolization of biologic glue during repair of aortic dissection. Ann Thorac Surg (1995) 1.52
Mast cells. Int J Dermatol (1995) 1.52
How best to fight that nasty itch - from new insights into the neuroimmunological, neuroendocrine, and neurophysiological bases of pruritus to novel therapeutic approaches. Exp Dermatol (2005) 1.51
GA(2)LEN skin test study II: clinical relevance of inhalant allergen sensitizations in Europe. Allergy (2009) 1.51
Effects of a pseudoallergen-free diet on chronic spontaneous urticaria: a prospective trial. Allergy (2009) 1.49
Control of murine hair follicle regression (catagen) by TGF-beta1 in vivo. FASEB J (2000) 1.48
Allergen extract-induced interleukin-10 in human memory B cells inhibits immunoglobulin E production. Clin Exp Allergy (2009) 1.47
Food allergy and non-allergic food hypersensitivity in children and adolescents. Clin Exp Allergy (2004) 1.45
Viruses and bacteria in acute asthma exacerbations--a GA² LEN-DARE systematic review. Allergy (2010) 1.45
A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist. Proc Natl Acad Sci U S A (2001) 1.43
Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy (2010) 1.42
Fatal recurrent subarachnoid hemorrhage after complete endovascular aneurysm occlusion. AJNR Am J Neuroradiol (2006) 1.40
The definition and diagnostic testing of physical and cholinergic urticarias--EAACI/GA2LEN/EDF/UNEV consensus panel recommendations. Allergy (2009) 1.39
Schnitzler's syndrome: diagnosis, treatment, and follow-up. Allergy (2013) 1.35
NMR solution structure of a complex of calmodulin with a binding peptide of the Ca2+ pump. Biochemistry (1999) 1.33
Identification of a novel class of genomic DNA-binding sites suggests a mechanism for selectivity in target gene activation by the tumor suppressor protein p53. Genes Dev (1998) 1.31
p53 is essential for chemotherapy-induced hair loss. Cancer Res (2000) 1.29
EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy (2006) 1.28
Melanogenesis during the anagen-catagen-telogen transformation of the murine hair cycle. J Invest Dermatol (1994) 1.27
What is the physiological function of mast cells? Exp Dermatol (2003) 1.26
A simultaneous (15)N, (1)H- and (13)C, (1)H-HSQC with sensitivity enhancement and a heteronuclear gradient echo. J Biomol NMR (1995) 1.25
Impaired mast cell development and innate immunity in Mac-1 (CD11b/CD18, CR3)-deficient mice. J Immunol (1998) 1.25
Standard skin prick testing and sensitization to inhalant allergens across Europe--a survey from the GALEN network. Allergy (2005) 1.25
Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Br J Dermatol (2006) 1.24
Development and implementation of guidelines in allergic rhinitis – an ARIA-GA2LEN paper. Allergy (2010) 1.24
Allergic rhinitis management pocket reference 2008. Allergy (2008) 1.23
MeDALL (Mechanisms of the Development of ALLergy): an integrated approach from phenotypes to systems medicine. Allergy (2011) 1.22
GA2LEN (Global Allergy and Asthma European Network) addresses the allergy and asthma 'epidemic'. Allergy (2009) 1.22
Characterization of functional vanilloid receptors expressed by mast cells. Blood (1998) 1.21
Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper. Allergy (2008) 1.20
p53 Involvement in the control of murine hair follicle regression. Am J Pathol (2001) 1.19
Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria. Allergy (2014) 1.16
Undertreatment of rhinitis symptoms in Europe: findings from a cross-sectional questionnaire survey. Allergy (2007) 1.16
Re-engineering the toilet for sustainable waste water management. Environ Sci Technol (2001) 1.14
Rupatadine in allergic rhinitis and chronic urticaria. Allergy (2008) 1.13
Epidemiology of urticaria: a representative cross-sectional population survey. Clin Exp Dermatol (2010) 1.12
Antibacterial effects of cefroxadine, cephalexin and cephradine in a new in vitro pharmacokinetic model. J Antibiot (Tokyo) (1982) 1.11
Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy (2013) 1.09
Important research questions in allergy and related diseases: 3-chronic rhinosinusitis and nasal polyposis - a GALEN study. Allergy (2009) 1.08
Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry (2008) 1.08
The German version of the Chronic Urticaria Quality-of-Life Questionnaire: factor analysis, validation, and initial clinical findings. Allergy (2009) 1.07
Mast cell involvement in murine hair growth. Dev Biol (1994) 1.06
Chronic urticaria: an internet survey of health behaviours, symptom patterns and treatment needs in European adult patients. Br J Dermatol (2008) 1.06
ARIA-suggested drugs for allergic rhinitis: what impact on quality of life? A GA2LEN review. Allergy (2008) 1.05
Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy (2008) 1.04
Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells. Oncogene (2007) 1.04
GA2LEN skin test study III: minimum battery of test inhalent allergens needed in epidemiological studies in patients. Allergy (2009) 1.03
Mast cells as initiators of immunity and host defense. Exp Dermatol (2001) 1.02
Effectiveness of a procalcitonin algorithm to guide antibiotic therapy in respiratory tract infections outside of study conditions: a post-study survey. Eur J Clin Microbiol Infect Dis (2009) 1.01
In vivo increase in resistance to ciprofloxacin in Escherichia coli associated with deletion of the C-terminal part of MarR. Antimicrob Agents Chemother (2000) 1.01
Matrix metalloproteinase-9: a novel biomarker for monitoring disease activity in patients with chronic urticaria patients? Allergy (2009) 1.00
Potential immunocompetence of proteolytic fragments produced by proteasomes before evolution of the vertebrate immune system. J Exp Med (1997) 1.00